
    
      30-day, 6-month, and 12-month clinical follow-up and 6 to 9-month IVUS or SCA follow-up to
      measure long-term efficiency of Excel stent in the inhibition of restenosis as well as the
      safety after the cessation of the 6-month anti-platelet drug treatment.
    
  